What is Enlaza Therapeutics worth?
$295.0Mlast known valuation
Enlaza Therapeutics last raised $15.0M in its Early Stage VC (Aug 2025).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Enlaza Therapeutics
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Aug 2025 | Early Stage VC | $15.0M | ▮ | ▮ |
| Apr 2024 | Later Stage VC | $84.0M | ▮ | ▮ |
| Mar 2021 | Early Stage VC | $35.3M | ▮ | ▮ |
How Enlaza Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Enlaza Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- What is Enlaza Therapeutics worth?
- Enlaza Therapeutics's last known valuation is $295.0M.
- How much has Enlaza Therapeutics raised?
- Enlaza Therapeutics has raised $176.0M in total funding across 3 recorded rounds.
- When did Enlaza Therapeutics last raise?
- Enlaza Therapeutics last raised in Aug 2025 (Early Stage VC), raising $15.0M.